Pier Capital LLC Sells 1,335 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Pier Capital LLC lessened its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 1.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 102,128 shares of the company’s stock after selling 1,335 shares during the quarter. Pier Capital LLC owned approximately 0.16% of Vera Therapeutics worth $4,319,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of VERA. AlphaQuest LLC acquired a new position in Vera Therapeutics in the fourth quarter valued at approximately $34,000. KBC Group NV raised its position in shares of Vera Therapeutics by 127.2% during the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock valued at $105,000 after acquiring an additional 1,387 shares during the last quarter. Moors & Cabot Inc. acquired a new position in shares of Vera Therapeutics in the 4th quarter valued at $220,000. E Fund Management Co. Ltd. boosted its position in shares of Vera Therapeutics by 22.3% in the 4th quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company’s stock worth $262,000 after purchasing an additional 1,130 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Vera Therapeutics by 109.4% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 9,407 shares of the company’s stock worth $416,000 after purchasing an additional 4,914 shares during the period. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Stock Up 0.3 %

Vera Therapeutics stock opened at $27.15 on Tuesday. The company has a 50 day moving average of $31.50 and a 200-day moving average of $39.20. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics, Inc. has a twelve month low of $25.99 and a twelve month high of $51.61. The stock has a market capitalization of $1.73 billion, a PE ratio of -10.40 and a beta of 1.17.

Vera Therapeutics (NASDAQ:VERA) last announced its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.11. On average, equities research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Wolfe Research initiated coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 target price on the stock. JPMorgan Chase & Co. cut their price target on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 4th. The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $58.00 price objective for the company. Finally, Guggenheim increased their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $64.67.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total value of $730,450.00. Following the sale, the chief executive officer now owns 143,603 shares in the company, valued at approximately $5,993,989.22. The trade was a 10.86 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 21.70% of the stock is owned by insiders.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.